newsfilter
← Latest News
GlobeNewswire·

BioPharma Engages LexaGene in Second Feasibility Study

BEVERLY, Mass. , Dec. 16, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB:LXXGF, TSXV:LXG) ("LexaGene" or the "Company"), an innovative, molecular diagnostics company that has commercialized the MiQLab®